Fig. 1: Overview of mutation statistics and mutation-survival associations. | Nature Communications

Fig. 1: Overview of mutation statistics and mutation-survival associations.

From: Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancers

Fig. 1

a Proportion of patients in each cancer with a given gene mutated (normalized per row). b Prognostic effects of mutations in individual genes on overall survival (OS), measured by adjusted hazard ratio (HR) with two-sided Wald test. Genes that are significantly correlated with OS (P < 0.05) in a cancer type are colored red or blue. Red (blue) indicates that mutations in that gene have negative (positive) prognostic effects on the survival of patients. Genes that are not significantly associated with patient outcomes are shown as a gray square. Here we focus on 20 types of cancers including advanced non-small cell lung cancer (aNSCLC), metastatic breast cancer (mBC), metastatic colorectal cancer (mCRC), metastatic pancreatic cancer (mPCa), ovarian cancer (OC), metastatic prostate cancer (PC), gastric cancer (GC), advanced melanoma (aMel), advanced bladder cancer (aBCa), endometrial carcinoma (EC), metastatic renal cell carcinoma (mRCC), head and neck cancer (HNC), small-cell lung cancer (SCLC), multiple myeloma (MM), acute myeloid leukemia (AML), hepatocellular carcinoma (HCC), diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

Back to article page